Eckert & Ziegler: European Commission Confirms European Approval for YTTRIGA

January 21, 2011

BERLIN, January 21, 2011 /PRNewswire-FirstCall/ — Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in
radioactive compounds for the treatment of cancer, has renewed the approval
of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five
years ago the European Medicines Agency EMA approved this drug for the first
time and as a result of the current renewal process the drug has now been
granted an indefinite approval.

YTTRIGA is used as an active component in the preparation of numerous
radiopharmaceuticals for the treatment of liver, intestinal and blood cancers
as well as for neuroendocrine tumours. YTTRIGA is coupled with a
tumour-specific peptide or with an antibody which recognizes cancer cells and
binds to them maximizing the dose of ionizing radiation to the cancerous
cells and minimizing radiation exposure to healthy cells.

Pharmaceutical grade YTTRIGA is produced under cGMP in Eckert & Ziegler’s
clean room facility in Braunschweig, from which it is shipped worldwide to
radiopharmacy facilities that use it in radiolabeling preparations.

The Eckert & Ziegler Group of Companies has around 540 employees is one
of the world’s largest providers of isotope technology for radiotherapy and
nuclear medicine.

The Board of Directors

If you have any questions please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations,
Robert-Rossle-Str. 10, 13125 Berlin, Phone: +49(0)30-94-10-84-138, Fax -112,
e-mail: karolin.riehle@ezag.de, http://www.ezag.de

SOURCE Eckert & Ziegler AG

Source: newswire

comments powered by Disqus